Limits...
Prognostic significance of promyelocytic leukemia expression in gastrointestinal stromal tumor; integrated proteomic and transcriptomic analysis.

Ichikawa H, Yoshida A, Kanda T, Kosugi S, Ishikawa T, Hanyu T, Taguchi T, Sakumoto M, Katai H, Kawai A, Wakai T, Kondo T - Cancer Sci. (2014)

Bottom Line: Among the 2555 genes analyzed, we found that promyelocytic leukemia (PML), a tumor suppressor gene, was significantly downregulated in I-GIST at both the protein and mRNA levels (P < 0.01; fold difference ≥2.0).Immunohistochemistry of 254 additional cases from multiple clinical facilities showed that PML-negative cases were significantly frequent in the I-GIST group (P < 0.001).The 5-year recurrence-free survival rate was significantly lower in the PML-negative than in the PML-positive cases (60.1% vs 91.7%; P < 0.001).

View Article: PubMed Central - PubMed

Affiliation: Division of Pharmacoproteomics, National Cancer Center Research Institute, Tokyo, Japan; Division of Digestive and General Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.

Show MeSH

Related in: MedlinePlus

The stratified Kaplan–Meier analysis of recurrence-free survival. The cases were stratified according to the tumor site (a–c), and stratified according to recurrence risk classification of the NIH consensus criteria (d–f).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4317774&req=5

fig03: The stratified Kaplan–Meier analysis of recurrence-free survival. The cases were stratified according to the tumor site (a–c), and stratified according to recurrence risk classification of the NIH consensus criteria (d–f).

Mentions: We then examined the prognostic value of PML expression in cases stratified according to the tumor site or NIH consensus criteria (Fig.3). In the S-GIST group, the 5-year RFS rate was 61.2% for PML-negative cases and 94.2% for PML-positive cases (P < 0.001; Fig.3a). In contrast, in the I-GIST and other anatomical tumor site group, the difference between PML-positive and negative cases was not statistically significant (Fig.3b,c). With regard to the NIH consensus criteria, the RFS rate was significantly lower in PML-negative than in PML-positive cases within each risk group (Fig.3d–f).


Prognostic significance of promyelocytic leukemia expression in gastrointestinal stromal tumor; integrated proteomic and transcriptomic analysis.

Ichikawa H, Yoshida A, Kanda T, Kosugi S, Ishikawa T, Hanyu T, Taguchi T, Sakumoto M, Katai H, Kawai A, Wakai T, Kondo T - Cancer Sci. (2014)

The stratified Kaplan–Meier analysis of recurrence-free survival. The cases were stratified according to the tumor site (a–c), and stratified according to recurrence risk classification of the NIH consensus criteria (d–f).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4317774&req=5

fig03: The stratified Kaplan–Meier analysis of recurrence-free survival. The cases were stratified according to the tumor site (a–c), and stratified according to recurrence risk classification of the NIH consensus criteria (d–f).
Mentions: We then examined the prognostic value of PML expression in cases stratified according to the tumor site or NIH consensus criteria (Fig.3). In the S-GIST group, the 5-year RFS rate was 61.2% for PML-negative cases and 94.2% for PML-positive cases (P < 0.001; Fig.3a). In contrast, in the I-GIST and other anatomical tumor site group, the difference between PML-positive and negative cases was not statistically significant (Fig.3b,c). With regard to the NIH consensus criteria, the RFS rate was significantly lower in PML-negative than in PML-positive cases within each risk group (Fig.3d–f).

Bottom Line: Among the 2555 genes analyzed, we found that promyelocytic leukemia (PML), a tumor suppressor gene, was significantly downregulated in I-GIST at both the protein and mRNA levels (P < 0.01; fold difference ≥2.0).Immunohistochemistry of 254 additional cases from multiple clinical facilities showed that PML-negative cases were significantly frequent in the I-GIST group (P < 0.001).The 5-year recurrence-free survival rate was significantly lower in the PML-negative than in the PML-positive cases (60.1% vs 91.7%; P < 0.001).

View Article: PubMed Central - PubMed

Affiliation: Division of Pharmacoproteomics, National Cancer Center Research Institute, Tokyo, Japan; Division of Digestive and General Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.

Show MeSH
Related in: MedlinePlus